BIOSYNEX and its subsidiary ProciseDx expand their presence in North America thanks to a new agreement

ProciseDx, a wholly owned subsidiary of BIOSYNEX, announced an exclusive distribution agreement with Revvity EUROIMMUN US for its ProciseDx diagnostic platform in the United States and Canada. This platform, which obtained FDA authorization in September 2023, allows the dosing of biological drugs used in inflammatory bowel diseases.

This collaboration marks an important milestone for ProciseDx, leveraging EUROIMMUN US' leadership position in the in vitro diagnostics industry. The agreement also aims to improve the management of treatments for patients with IBD by offering immediate results, thus facilitating more personalized therapeutic monitoring.

The high cost of IBD treatments in the United States makes this agreement particularly relevant, as it could help optimize the effectiveness of expensive drug treatments, potentially improving patients' quality of life while controlling healthcare costs.

The established presence of EUROIMMUN US should allow ProciseDx to effectively access the North American market, while maintaining direct links with potential future customers already in discussions for the referencing of this diagnostic tool.